Research Analysts Set Expectations for Exelixis Q4 Earnings

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Stock analysts at Zacks Research increased their Q4 2026 EPS estimates for Exelixis in a research note issued to investors on Tuesday, July 1st. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will post earnings of $0.76 per share for the quarter, up from their prior estimate of $0.75. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis' Q2 2027 earnings at $0.74 EPS and FY2027 earnings at $2.95 EPS.

A number of other research firms also recently commented on EXEL. Citigroup upped their price objective on Exelixis from $45.00 to $56.00 and gave the company a "buy" rating in a report on Thursday, May 15th. Jefferies Financial Group set a $50.00 price target on Exelixis and gave the company a "buy" rating in a report on Tuesday, June 24th. Royal Bank Of Canada reissued an "outperform" rating and set a $40.00 price target on shares of Exelixis in a research report on Wednesday, May 14th. Benchmark reissued a "neutral" rating on shares of Exelixis in a research note on Monday, June 23rd. Finally, Wall Street Zen downgraded Exelixis from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 15th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.56.

Exelixis Stock Up 3.6%

Exelixis stock opened at $45.91 on Friday. Exelixis has a 12-month low of $21.86 and a 12-month high of $49.62. The stock has a 50-day simple moving average of $41.71 and a 200 day simple moving average of $37.58. The stock has a market capitalization of $12.52 billion, a price-to-earnings ratio of 20.87, a P/E/G ratio of 0.89 and a beta of 0.28.

Insider Buying and Selling at Exelixis

In related news, EVP Patrick J. Haley sold 126,383 shares of the firm's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the completion of the sale, the executive vice president directly owned 446,459 shares of the company's stock, valued at approximately $21,412,173.64. This trade represents a 22.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Christopher J. Senner sold 100,000 shares of the company's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $46.00, for a total value of $4,600,000.00. Following the transaction, the chief financial officer owned 967,842 shares in the company, valued at $44,520,732. This trade represents a 9.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 458,113 shares of company stock valued at $21,024,817. Insiders own 2.82% of the company's stock.

Institutional Investors Weigh In On Exelixis

A number of large investors have recently modified their holdings of EXEL. Raymond James Financial Inc. acquired a new position in Exelixis in the fourth quarter valued at $17,046,000. Proficio Capital Partners LLC purchased a new position in shares of Exelixis during the fourth quarter worth approximately $706,000. Wells Fargo & Company MN increased its holdings in shares of Exelixis by 1,637.9% in the 4th quarter. Wells Fargo & Company MN now owns 746,286 shares of the biotechnology company's stock valued at $24,851,000 after acquiring an additional 703,343 shares during the period. Smartleaf Asset Management LLC boosted its stake in Exelixis by 958.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,942 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 2,664 shares during the period. Finally, Park Avenue Securities LLC increased its stake in Exelixis by 10.6% in the first quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company's stock valued at $272,000 after purchasing an additional 707 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.